JP2020511457A - ヒドロキシアルキルチアジアゾール誘導体のｎ−ホスホノキシメチルプロドラッグ - Google Patents

ヒドロキシアルキルチアジアゾール誘導体のｎ−ホスホノキシメチルプロドラッグ Download PDF

Info

Publication number
JP2020511457A
JP2020511457A JP2019549506A JP2019549506A JP2020511457A JP 2020511457 A JP2020511457 A JP 2020511457A JP 2019549506 A JP2019549506 A JP 2019549506A JP 2019549506 A JP2019549506 A JP 2019549506A JP 2020511457 A JP2020511457 A JP 2020511457A
Authority
JP
Japan
Prior art keywords
compound
ethyl
chloro
imidazol
thiadiazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019549506A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020511457A5 (https=
Inventor
クマール ケラ、マノジ
クマール ケラ、マノジ
チンタマン ドゥンブレ、ナレッシュ
チンタマン ドゥンブレ、ナレッシュ
カーン、パーシャ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of JP2020511457A publication Critical patent/JP2020511457A/ja
Publication of JP2020511457A5 publication Critical patent/JP2020511457A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2019549506A 2017-03-14 2018-03-13 ヒドロキシアルキルチアジアゾール誘導体のｎ−ホスホノキシメチルプロドラッグ Pending JP2020511457A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201711008754 2017-03-14
IN201711008754 2017-03-14
PCT/JP2018/010670 WO2018169092A1 (en) 2017-03-14 2018-03-13 N-phosphonoxymethyl prodrugs of hydroxyalkyl thiadiazole derivatives

Publications (2)

Publication Number Publication Date
JP2020511457A true JP2020511457A (ja) 2020-04-16
JP2020511457A5 JP2020511457A5 (https=) 2020-07-27

Family

ID=62002340

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019549506A Pending JP2020511457A (ja) 2017-03-14 2018-03-13 ヒドロキシアルキルチアジアゾール誘導体のｎ−ホスホノキシメチルプロドラッグ

Country Status (6)

Country Link
US (1) US10752647B2 (https=)
EP (1) EP3596071A1 (https=)
JP (1) JP2020511457A (https=)
CA (1) CA3056571C (https=)
TW (1) TW201840322A (https=)
WO (1) WO2018169092A1 (https=)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011026305A (ja) * 2009-06-24 2011-02-10 Daiichi Sankyo Co Ltd イミダゾールカルボニル化合物を含有する医薬組成物
JP2013537188A (ja) * 2010-09-13 2013-09-30 アドヴィナス・セラピューティックス・リミテッド Ａ２ｂアデノシン受容体アンタゴニストのプロドラッグとしてのプリン化合物、これらの方法および薬剤の適用
JP2014196369A (ja) * 2007-12-27 2014-10-16 第一三共株式会社 イミダゾールカルボニル化合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200526626A (en) 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
WO2006087544A2 (en) 2005-02-18 2006-08-24 Astrazeneca Ab Pyrrole derivatives as dna gyrase and topoisomerase inhibitors
NZ561613A (en) 2005-02-18 2010-12-24 Astrazeneca Ab Antibacterial piperidine derivatives
CN101163674A (zh) 2005-02-18 2008-04-16 阿斯利康(瑞典)有限公司 作为dna促旋酶和拓扑异构酶抑制剂的吡咯衍生物
US20080269214A1 (en) 2005-03-04 2008-10-30 Astrazeneca Ab Pyrrole Derivatives as Dna Gyrase and Topoisomerase Inhibitors
CN101171250A (zh) 2005-03-04 2008-04-30 阿斯利康(瑞典)有限公司 具有抗菌活性的氮杂环丁烷和吡咯的三环衍生物
JP2009520785A (ja) 2005-12-23 2009-05-28 アストラゼネカ アクチボラグ 抗菌性のピロロピリジン、ピロロピリミジン、及びピロロアゼピン
WO2008020229A2 (en) 2006-08-17 2008-02-21 Astrazeneca Ab Antibacterial pyrrolecarboxamides
WO2008020227A2 (en) 2006-08-17 2008-02-21 Astrazeneca Ab Antibacterial pyrrolecarboxamides
TW200819437A (en) 2006-08-17 2008-05-01 Astrazeneca Ab Chemical compounds
TW200906412A (en) 2007-06-12 2009-02-16 Astrazeneca Ab Piperidine compounds and uses thereof
US20120108565A1 (en) 2008-07-30 2012-05-03 Lalima Sharma Pyrrole carboxylic acid derivatives as antibacterial agents
TW201026694A (en) 2008-12-12 2010-07-16 Astrazeneca Ab Compound 468
TW201026695A (en) 2008-12-12 2010-07-16 Astrazeneca Ab Piperidine compounds and uses thereof-596
WO2014057415A2 (en) 2012-10-10 2014-04-17 Vitas Pharma Research Pvt Ltd Inhibitors of dna gyrase for the treatment of bacterial infections
KR20180054650A (ko) 2015-09-30 2018-05-24 다이이찌 산쿄 가부시키가이샤 히드록시알킬 티아디아졸 유도체

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014196369A (ja) * 2007-12-27 2014-10-16 第一三共株式会社 イミダゾールカルボニル化合物
JP2011026305A (ja) * 2009-06-24 2011-02-10 Daiichi Sankyo Co Ltd イミダゾールカルボニル化合物を含有する医薬組成物
JP2013537188A (ja) * 2010-09-13 2013-09-30 アドヴィナス・セラピューティックス・リミテッド Ａ２ｂアデノシン受容体アンタゴニストのプロドラッグとしてのプリン化合物、これらの方法および薬剤の適用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEMISTRY & BIODIVERSITY, vol. 6, JPN6021016764, 2009, pages 2071 - 2083, ISSN: 0004608617 *
PRODRUGS AND TARGETED DELIVERY: TOWARDS BETTER ADME PROPERTIES, vol. 47, JPN6021016766, 2010, pages 111 - 131, ISSN: 0004608618 *
化学便覧 応用化学編, vol. 第6版, JPN6021038323, 30 January 2003 (2003-01-30), ISSN: 0004608619 *

Also Published As

Publication number Publication date
EP3596071A1 (en) 2020-01-22
CA3056571A1 (en) 2018-09-20
CA3056571C (en) 2021-11-23
TW201840322A (zh) 2018-11-16
US20200040019A1 (en) 2020-02-06
WO2018169092A1 (en) 2018-09-20
US10752647B2 (en) 2020-08-25

Similar Documents

Publication Publication Date Title
ES2244666T3 (es) Derivados de acidos 3-(heteroaril-acetamido)-2-oxoazetidina-1-sulfonicos utilizados como agentes antibacterianos.
CN101031572A (zh) (r/s)利福霉素衍生物，它们的制备和药物组合物
JP6130600B2 (ja) トリサイクリックベンズオキサボロール化合物、その製造方法および用途
EP0603887B1 (en) Bicyclic amine derivatives
AU2016330271B2 (en) Hydroxyalkyl thiadiazole derivatives
RU2522582C2 (ru) Новые противомикробные средства
US7759482B2 (en) Aminoglycosides as antibiotics
JP2020511457A (ja) ヒドロキシアルキルチアジアゾール誘導体のｎ−ホスホノキシメチルプロドラッグ
JP2020511457A5 (https=)
KR20000048687A (ko) 피리도벤족사진 유도체
HK1252275B (en) Hydroxyalkyl thiadiazole derivatives
US20080242597A1 (en) Antibiotic compounds
WO2005073238A1 (ja) ピリドベンズオキサジン誘導体
WO1996024593A1 (en) Heterocyclic spiro derivatives
CN105452219A (zh) 新型吡咯衍生物
HK1122210B (en) Quinoline derivatives as antibacterial agents

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200610

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200610

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210707

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211005